Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
461-480 of 1,738 trials

Cleft Palate Treatment: Tissue-Engineered Oral Mucosa Substitute

We are testing a new tissue-engineered substitute for patients with cleft palate to see if it is safe and effective for healing and improving quality of life. The study will compare outcomes with standard treatments.

Cleft Lip and Palate>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyOrthopedics and TraumatologyPediatrics

Ulcerative Colitis: Novel Rifamycin Enema

We are testing a new rifamycin solution for patients with mild to moderate left-sided ulcerative colitis. The study aims to see if it helps improve symptoms and induce remission compared to a placebo.

Left-Sided Ulcerative Colitis3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Nerve Damage from Cancer: New Immunotherapy Approach

We are studying a combination of treatments for patients with anti-Hu-associated nerve damage due to cancer. The goal is to see if this early immunotherapy improves symptoms and helps patients live longer without cancer progression.

Paraneoplastic Neurological Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Bone Health: Identifying Risks from Glucocorticoids

We are studying how to find biomarkers that indicate a risk of bone disease in people taking glucocorticoids. This research may help improve monitoring and prevention strategies for affected individuals.

Secondary Osteoporosis≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyRheumatology

Non-Hodgkin Lymphoma: IPH6501 Treatment Study

We are investigating a new drug, IPH6501, for patients with relapsed or refractory Non-Hodgkin Lymphoma. The study focuses on its safety and early signs of effectiveness in treating this type of cancer.

Refractory Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Prostate Cancer: Pembrolizumab Combination Therapy

We are studying a new combination therapy with pembrolizumab for men with metastatic castration-resistant prostate cancer. The trial aims to evaluate its safety and how well it reduces PSA levels compared to standard treatments.

Metastatic Castration-Resistant Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Gene Therapy for Crigler-Najjar Syndrome: GNT0003

We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.

Crigler-Najjar Syndrome>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteHepatology

Triple-Negative Breast Cancer: Keytruda with Chemotherapy

We are studying how different chemotherapy regimens combined with Keytruda affect the immune response in patients with early-stage triple-negative breast cancer. The goal is to find the most effective treatment approach for this specific cancer type.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Persistent Corneal Epithelial Defects: NEXAGON Gel Study

We are evaluating the safety and effectiveness of NEXAGON (Lufepirsen Ophthalmic Gel) for individuals with persistent corneal epithelial defects. The study aims to see if it helps heal the cornea better than a placebo.

Persistent Corneal Epithelial DefectEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesOphthalmology

Long-Term Study on Gene-Modified Cell Treatments

We are evaluating the long-term health effects of gene-modified cells in participants, especially children and adolescents. This includes monitoring for serious side effects and overall growth and development.

Solid and Hematological Malignancies>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncologyRheumatology

Autoimmune Cytopenias: Povetacicept Study

We are testing a new treatment called povetacicept for individuals with autoimmune cytopenias. The study aims to evaluate its safety and effectiveness in managing this condition.

Autoimmune Cytopenias6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Cirrhosis Treatment: Albumin and Enoxaparin Study

We are testing a new combination therapy of albumin and enoxaparin for patients with decompensated cirrhosis at high risk of complications. The study aims to assess safety and explore how this treatment may affect the disease.

Cirrhosis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Prostate Cancer: uPAR PET Imaging Study

We are investigating a new imaging method to help classify prostate cancer grades in men with localized, untreated disease. This study aims to assess the safety and effectiveness of this non-invasive technique.

Prostate Cancer≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Breast Cancer: Vepdegestrant and Samuraciclib Study

We are investigating the safety and effectiveness of a new oral medication combined with another treatment for adults with advanced or metastatic hormone receptor-positive breast cancer. This study aims to find better treatment options for patients facing this condition.

Advanced Breast CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Scleroderma-Related Lung Disease: Investigational Treatments

We are studying new treatments for interstitial lung disease in people with scleroderma to see if they improve lung function and overall health compared to a placebo.

Interstitial Lung Disease due to Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonologyRheumatology

Non-Small Cell Lung Cancer: Divarasib with Other Therapies

We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Zilovertamab Vedotin for Pediatric Cancers

We are studying a new treatment for children and young adults with blood cancers and solid tumors. The trial aims to assess its safety and how well it may work in these young patients.

Blood Cancers and Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPediatrics

MECP2 Duplication Syndrome: ION440 Treatment Study

We are testing a new treatment called ION440 to see if it is safe and well-tolerated in patients with MECP2 Duplication Syndrome. This study will also look at how the drug moves through the body.

MECP2 Duplication SyndromeSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematology

Upper Limb Spasticity: New Botulinum Toxin Treatment

We are investigating a new injection for adults with upper limb spasticity to see if it is safe and effective compared to existing treatments. This study will help us understand how well it works over time.

Upper Limb Spasticity1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Ruxolitinib Rollover Study for Cancer Patients

We are providing continued access to ruxolitinib for patients who have previously participated in related studies. The goal is to evaluate the safety of ruxolitinib alone or with other cancer treatments.

MyelofibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology